Amneal pharmaceuticals, inc. enters licensing agreement with kashiv biosciences, llc

Amneal pharmaceuticals, inc. announced that it has entered into a licensing agreement with kashiv biosciences, llc for the development and commercialization of kashiv's orphan drug k127 (pyridostigmine) for the treatment of myasthenia gravis. through this partnership, amneal gains exclusive rights within the united states to the new drug application and commercialization of k127.
AMRX Ratings Summary
AMRX Quant Ranking